Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR Stock Report

Market Cap: US$8.7b

Arrowhead Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ARWR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
17 Dec 25SellUS$5,443,462Christopher AnzaloneIndividual85,000US$66.30
16 Dec 25SellUS$12,348,802Christopher AnzaloneIndividual184,298US$69.96
05 Dec 25SellUS$991,738Michael PerryIndividual16,250US$61.03
28 Nov 25SellUS$493,413Mauro FerrariIndividual8,750US$56.39
11 Apr 25SellUS$1,533,337Christopher AnzaloneIndividual141,122US$11.76
13 Mar 25SellUS$774,975Christopher AnzaloneIndividual51,425US$15.07

Insider Trading Volume

Insider Buying: ARWR insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ARWR?
Owner TypeNumber of SharesOwnership Percentage
State or Government54,5500.0401%
Public Companies2,660,9891.96%
Individual Insiders5,260,3923.87%
Hedge Funds10,900,0008.02%
General Public14,528,78310.7%
Institutions102,474,94375.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 72.48% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.9%
BlackRock, Inc.
20,224,825US$1.3b4.12%0.02%
11.8%
The Vanguard Group, Inc.
16,035,870US$1.0b3.29%0.01%
8.02%
Avoro Capital Advisors LLC
10,900,000US$696.3m2.83%7.57%
4.71%
State Street Global Advisors, Inc.
6,397,364US$408.7m0.41%0.01%
4.24%
FMR LLC
5,756,981US$367.8m11.4%0.02%
3.67%
Slate Path Capital LP
4,982,000US$318.3m-4.78%4.11%
2.8%
Christopher Anzalone
3,805,926US$243.1m-2.94%no data
2.3%
Geode Capital Management, LLC
3,131,042US$200.0m5.12%0.01%
1.97%
UBS Asset Management AG
2,677,672US$171.0m-37.5%0.01%
1.96%
Artal Group S.A.
2,669,880US$170.6m0%3.57%
1.96%
Sarepta Therapeutics, Inc.
2,660,989US$170.0m0%no data
1.55%
Driehaus Capital Management LLC
2,099,398US$134.1m0%0.64%
1.53%
Arrowstreet Capital, Limited Partnership
2,081,689US$133.0m3,140%0.08%
1.42%
Norges Bank Investment Management
1,924,957US$123.0m0%0.01%
1.23%
Baker Bros. Advisors LP
1,670,762US$106.7m77.9%0.59%
1.06%
Marshall Wace LLP
1,436,840US$91.8m-33.4%0.11%
1%
The Goldman Sachs Group, Inc.
1,364,214US$87.1m-12.9%0.03%
0.99%
Charles Schwab Investment Management, Inc.
1,345,860US$86.0m15%0.01%
0.97%
Northern Trust Global Investments
1,311,590US$83.8m3.11%0.01%
0.86%
Morgan Stanley
1,161,954US$74.2m-1.52%0.01%
0.78%
Fisher Asset Management, LLC
1,053,794US$67.3m133%0.02%
0.74%
Woodline Partners LP
1,000,158US$63.9m34%0.29%
0.73%
Deerfield Management Company, L.P.
993,000US$63.4m0%0.81%
0.72%
Janus Henderson Group plc
973,567US$62.2m1,850%0.02%
0.6%
Western Financial Corporation
820,239US$52.4m0%20.9%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 06:44
End of Day Share Price 2026/01/06 00:00
Earnings2025/09/30
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arrowhead Pharmaceuticals, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
William PickeringBernstein
Jason Matthew GerberryBofA Global Research